Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- NIAGARAIndependent statistical analysis of Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- nic_physoIndependent statistical analysis of Acetylcholine, Tobacco Smoking, Genes and Nicotinic Receptors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02008292).
- Nicardipine vs Esmolol Craniotomy Emergence: Complete Statistical AnalysisIndependent statistical analysis of Nicardipine vs Esmolol Craniotomy Emergence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01951950).
- NICEIndependent statistical analysis of Neurogenic Intermittent Claudication Evaluation Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00905359).
- NICEIndependent statistical analysis of Nitrite, Isoquercetin and Endothelial Dysfunction (NICE) Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02552888).
- NICHEIndependent statistical analysis of N-of-1 Trials In Children With Hypertension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03461003).
- NICHEIndependent statistical analysis of Niche Trial: Navigated Inhibitory rTMS to Contralesional Hemisphere Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02089464).
- Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Dependence, Withdrawal and Replacement Therapy Assessed by PET Imaging: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01664741).
- Nicotine Lozenge Bioequivalence Study: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Lozenge Bioequivalence Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01536704).
- Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Pharmacokinetic and Pharmacodynamics Profile, Safety and Tolerability of P3L: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02532374).
- Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol): Complete Statistical AnalysisIndependent statistical analysis of Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol).: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Pharmacokinetics and Pharmacodynamics, Safety and Tolerability of P3P: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03369340).
- Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Receptor Density & Response to Nicotine Patch: Pt 2 Extended Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nicotine Reinforcement and Aversion in Young Adult Light Smokers: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Reinforcement and Aversion in Young Adult Light Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01495819).
- Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Replacement Therapy (NRT) and Bupropion Mechanisms of Effectiveness in Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Nicotine Withdrawal Symptoms and Smoking Relapse: Complete Statistical AnalysisIndependent statistical analysis of Nicotine Withdrawal Symptoms and Smoking Relapse: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01511614).
- Nicotine’s Potential Abuse With Menthol: Complete Statistical AnalysisIndependent statistical analysis of Nicotine's Potential Abuse With Menthol: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04535362).
- Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia: Complete Statistical AnalysisIndependent statistical analysis of Nicotinic Enhancement of Cognitive Remediation Training in Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02069392).
- Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study: Complete Statistical AnalysisIndependent statistical analysis of Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02312934).
- NICU-TECH RM9L-RS Probe ME Feasibility Study: Complete Statistical AnalysisIndependent statistical analysis of NICU-TECH RM9L-RS Probe ME Feasibility Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01181596).
- Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System: Complete Statistical AnalysisIndependent statistical analysis of Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- NIGWVIIndependent statistical analysis of Novel Interventions for GWVI: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02661997).
- NIH_HVX6Independent statistical analysis of Chewing and Oral Processing of Solid Food: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05594173).
- NIHO12Independent statistical analysis of Accuracy of Pulse Oximeters With Profound Hypoxia During Motion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04814342).
- NIKAIA 1Independent statistical analysis of To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus: primary endpoint results, effect estimate…
- NILOdeepRIndependent statistical analysis of Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR): Complete Statistical AnalysisIndependent statistical analysis of Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of…
- NIMBLeIndependent statistical analysis of Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NIMBLEIndependent statistical analysis of Novel Methods for Implementing Measurement-Based Care for Youth in Low-resource Environments: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- NIMBUSIndependent statistical analysis of A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple…
- NIMBUSIndependent statistical analysis of A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma.: primary endpoint results, effect estimate with confidence interval, sample-size…
- Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV: Complete Statistical AnalysisIndependent statistical analysis of Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- NINJA NGALIndependent statistical analysis of Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC): Complete Statistical AnalysisIndependent statistical analysis of Nintedanib For HER2-Negative Metastatic Inflammatory Breast Cancer (MIBC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02389764).
- Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.: Complete Statistical AnalysisIndependent statistical analysis of Ninvasive Cardiac Output Measurements During Cesarean Delivery Under Spinal Anesthesia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01928797).
- NIPUTFDIndependent statistical analysis of Neuroimaging in Patients Undergoing TMS for Depression: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02974296).
- NIR-FlowIndependent statistical analysis of Transcranial Near-Infrared Light in Healthy Subjects: a Cerebral Blood Flow Study With Diffuse Correlation Spectroscopy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- NIRAFIndependent statistical analysis of Evaluating Impact of NIRAF Detection for Identifying Parathyroid Glands During Parathyroidectomy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Niraparib + Dostarlimab + RT in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib + Dostarlimab + RT in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04409002).
- Niraparib + Dostarlimab In BRCA Mutated Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib + Dostarlimab In BRCA Mutated Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04584255).
- Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- NIRVANAIndependent statistical analysis of A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause: primary endpoint results, effect estimate with confidence…
- NIRVANAIndependent statistical analysis of Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03220230).